1. Why Q4 2025 matters so much for the NVAX story

If you only look at the stock price, Novavax still looks like a broken COVID chart trying to find a new equilibrium in the single-digit area. The shape screams “post-bubble trauma”. But if you look at the Q4 2025 and full-year numbers, the image is very different from the 2022–2023 horror show. In Q4 2025, total revenue reached roughly 147 million dollars, about two thirds higher than the same quarter a year ago, and the company posted a GAAP net profit of 17.5 million dollars, or 0.11 dollars per share, against an 81 million loss in Q4 2024.

For the full year 2025, revenue crossed the 1.1 billion dollar mark, with a large component coming from the 500 million dollar Sanofi upfront and a stream of milestones tied to the COVID/flu combination program and the transfer of marketing authorisations to Sanofi in Europe and the US. The key point is not that every dollar is recurring – it is not – but that the P&L now reflects a live platform where multiple counterparties pay for Matrix-M and for Novavax’s ability to deliver adjuvant technology and supply at scale.

On the cost side, Novavax has continued to do the ugly part of the work: cost of sales more than halved year-on-year for the full year 2025, R&D and SG&A were brought down below previous guidance, and management tightened the expense targets for 2026 and beyond. At year end, the company still had 751 million dollars in cash and equivalents, even after a long restructuring phase and heavy repayments on legacy obligations.

Put together, these elements explain why Q4 2025 is not “just another quarter” in a slow bleed. It is the first quarter where Novavax behaves like what we have been describing on Merlintrader since the Sanofi agreement: a technology platform with leverage to other people’s pipelines, rather than a niche COVID vaccine trying to fight mRNA giants market by market.

2. What actually changed in the P&L: revenue mix and margins

3. 2026 guidance: smaller top line, but cleaner quality

One of the easiest misunderstandings around the new guidance is to look at the 2026 revenue range – 230 to 270 million dollars of Adjusted Total Revenue – and conclude that the company is shrinking dramatically after a 1.1 billion dollar 2025. That is not how the framework is defined. The figure explicitly excludes Sanofi supply sales, royalties and Sanofi influenza-COVID-19 combination and Matrix-M milestones. Those items are treated as upside on top of the base case and will depend heavily on Sanofi’s own commercial and regulatory timeline.

Within the 230–270 million dollars range, Novavax breaks down the building blocks in a way that is very informative:

• Nuvaxovid product sales: 35–45 million dollars, under existing purchase and commercial agreements.
• Adjusted supply sales: 40–50 million dollars, mainly tied to Serum Institute’s R21/Matrix-M malaria vaccine and to COVID supply collaborations (Serum, Takeda).
• Licensing, royalties and other revenue: 155–175 million dollars, including 70–80 million dollars in R&D reimbursements from Sanofi, 50–60 million dollars in partner-related royalties and milestones (Pfizer, Serum and others, including the 30 million Pfizer upfront) and around 35 million dollars of amortisation of the Sanofi upfront and database-lock milestones.

In other words, the “core” 2026 story is deliberately modest on direct product sales and much more geared towards recurring, contractually defined cash flows from partners. That is consistent with what we have been writing since the Sanofi agreement: Novavax is not trying to rebuild a fully integrated vaccine empire; it is trying to monetise a niche but valuable adjuvant technology across other people’s franchises.

On the expense side, management continues to guide towards profitability in 2028 on a non-GAAP basis. That timeline assumes that Sanofi’s COVID/flu combination reaches the market and that Matrix-M royalties ramp, while the early-stage pipeline moves into the clinic around 2027. None of this is guaranteed, but it is a coherent roadmap, and – crucially – it no longer depends on Novavax winning a brutal first-line COVID share battle against mRNA incumbents.

4. Sanofi + Pfizer + everyone else: Matrix-M as a real platform

The Q4 2025 press release does a good job of stitching together the platform elements that were spread across separate announcements in 2024–2025. On the Sanofi side, the existing co-exclusive licensing agreement gives Novavax:

• a 500 million dollar upfront payment, already in the bank;
• the potential for up to 700 million dollars in development, regulatory and launch milestones tied to the licensed COVID-19 products and COVID/flu combinations;
• double-digit tiered royalties on Sanofi’s sales of those products, once they reach the market.

During 2025 alone, Novavax booked about 225 million dollars in Sanofi milestones, including 50 million in Q4 when the marketing authorisations were transferred to Sanofi in the EU and US. Sanofi has also shared positive Phase 1/2 data for its influenza-COVID-19 combination programs and explicitly stated that it sees a high probability of demonstrating non-inferiority in Phase 3 against the current “two separate shots” standard.

On top of Sanofi, the Pfizer Matrix-M license announced in January 2026 adds a second, very visible pillar:

• 30 million dollars upfront, received in Q1 2026;
• up to 500 million dollars in development and sales milestones;
• tiered high mid-single digit royalties on Pfizer’s net sales of products that incorporate Matrix-M;
• a non-exclusive license covering up to two infectious disease areas – which means Novavax remains free to license Matrix-M to other partners and indications.

Around these two flagships, the Q4 release lists a growing ecosystem of material transfer agreements with large pharma players and an important proof point from the malaria franchise: R21/Matrix-M, marketed by Serum Institute of India, has already sold around 30 million doses since mid-2024 and has captured more than 80% market share in its target segment. Takeda has reached roughly 12% market share with Nuvaxovid in Japan, again a sign that Matrix-M can compete in real-world settings when embedded in strong distribution networks.

None of this guarantees that every program will move smoothly from early trials to commercial success, but the pattern is clear: the number of serious counterparties willing to underwrite Matrix-M is increasing, and the platform now spans COVID, flu combinations, malaria, and undisclosed infectious-disease and oncology settings.

5. Balance sheet, credit lines and dilution risk

At the end of 2025, Novavax reported 751 million dollars in cash, cash equivalents, marketable securities and restricted cash. That figure sits on top of a capital structure that has been reshaped repeatedly over the last few years, with convertible debt, government agreements, restructuring charges and multiple rounds of refinancing.

In parallel with the platform deals, the company has also put in place a credit facility with MidCap, initially drawing 50 million dollars and keeping additional tranches available subject to certain conditions. That line is a double-edged sword: it offers non-dilutive liquidity if needed, but it also adds fixed obligations in a context where the base-case revenue framework for 2026 is still modest.

From a RunUP Biotech perspective, the key point is not to pretend that dilution risk has magically disappeared. It has not. But the combination of:

• a solid cash cushion;
• contracted economics from Sanofi and Pfizer that extend beyond 2026;
• and a much leaner cost base

means that the NVAX story today is very different from the period where the company was effectively burning through its COVID cash while fighting regulatory delays and manufacturing issues. Dilution is still on the table as a tool, especially if new programmes move faster than expected, but it is no longer the only obvious path to survival.

6. Early-stage pipeline and optionality beyond COVID

One of the more subtle lines in the Q4 2025 communication is the reference to the early-stage pipeline, which the company aims to bring into the clinic as early as 2027. Most details remain under wraps, as you would expect at this stage, but a few points are worth keeping on your radar:

• The company has signed and expanded multiple MTAs in infectious diseases with large pharma players, suggesting that Matrix-M is being tested beyond COVID and flu.
• A new MTA with an oncology company was signed in Q4 2025, and another large-pharma MTA was expanded in February 2026 to cover an additional field.
• The R21/Matrix-M success effectively proves that the adjuvant can deliver real-world value in a completely different indication – malaria – where the sales dynamic and payer mix look very different from the COVID booster market.

These elements are far from being an investment case on their own, but they reinforce the core idea we have used throughout Merlintrader’s coverage: Matrix-M is not a COVID gimmick; it is a piece of immunology infrastructure that can be plugged into multiple vaccine platforms over time, provided Novavax maintains scientific credibility, manufacturing quality and regulatory compliance.

7. Sentiment – what Reddit, Stocktwits and X are saying

8. Key risks – what can still go wrong

Even with a good Q4 and an upgraded 2026 revenue framework, NVAX remains a high-risk name. A few risk clusters you should keep in mind when you revisit your own notes:

• Execution risk at partners: the core upside depends on Sanofi turning positive Phase 1/2 data for the COVID/flu combination into a successful Phase 3 and commercial launch, and on Pfizer pushing its Matrix-M programs through development. Novavax does not control those pipelines directly.
• Regulatory and political risk: as we have seen repeatedly in the United States, changes in recommended vaccination schedules, politicised narratives around non-mRNA vaccines and regulatory delays can have a disproportionate impact on demand.
• Concentration of economics: even in the platform version of the story, a large chunk of value is still tied to a small number of big agreements. If one of them underperforms or is delayed, the impact on cash flows can be material.
• Balance-sheet and refinancing risk: a 751 million dollar cash pile is comfortable compared to the historical lows, but it is not infinite, especially in a world where clinical development and manufacturing are expensive and macro conditions can change.
• Litigation and legacy issues: previous government contracts, manufacturing disputes and lawsuits can still create headlines and unexpected cash outflows.

9. How this fits the long-term Merlintrader NVAX stance

From day one, Merlintrader’s angle on Novavax has been simple but demanding: treat NVAX as a long-duration, high-volatility platform option, not as a one-off COVID lottery ticket. That stance – structurally bullish, but always aware of balance-sheet, regulatory and execution risk – is why the earlier pieces focused so heavily on:

• the structural economics of the Sanofi deal and its impact on solvency;
• the strategic reset at JPM 2026, where management openly shelved the “mini-Pfizer” dream and embraced a partner-driven model;
• the idea of Matrix-M as a platform that can plug into other people’s pipelines, including non-COVID indications.

The Q4 2025 numbers, the 2026 revenue framework and the Pfizer license take that thesis one step further. They do not eliminate the risks, and they do not turn NVAX into a low-beta cash cow. What they do is provide a coherent bridge between the survival-mode phase and a scenario where most of the heavy lifting on development and commercialisation is done by partners with much stronger balance sheets.

If you have been following NVAX with Merlintrader since the early core report, this deep dive is essentially a checkpoint: the long-term bullish platform narrative we have been running with is now visible in the financials and in the partner list, not just in slide decks and conference remarks. That does not tell you what to do with your own capital – that part is always on you – but it does change the quality of the information you can plug into your own process.